The Erythematosus Market was valued at USD 5.2 billion in 2024 and is projected to reach USD 10.1 billion by 2034, registering a CAGR of 6.8%. This growth trajectory is underpinned by several key factors, including the rising prevalence of erythematosus conditions, advancements in treatment options, and increasing awareness among healthcare professionals and patients. The demand for effective...